Global Epidemiology of Hip Fractures: Secular Trends in Incidence Rate, Post‐Fracture Treatment, and All‐Cause Mortality
Journal of Bone and Mineral Research · 2023-08 · 38 (8) · 1064-1075
DOI: 10.1002/jbmr.4821 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Bone and Mineral Research, online erschienen am 29.05.2023. Verfasst von Chor-Wing Sing und 43 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong SAR, China. Hauptthemen laut MEDLINE: Hip Fractures, Osteoporosis, Osteoporotic Fractures. Die Arbeit wurde bisher 661-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, Amgen.
Abstract (Originalsprache)
In this international study, we examined the incidence of hip fractures, postfracture treatment, and all‐cause mortality following hip fractures, based on demographics, geography, and calendar year. We used patient‐level healthcare data from 19 countries and regions to identify patients aged 50 years and older hospitalized with a hip fracture from 2005 to 2018. The age‐ and sex‐standardized incidence rates of hip fractures, post‐hip fracture treatment (defined as the proportion of patients receiving anti‐osteoporosis medication with various mechanisms of action [bisphosphonates, denosumab, raloxifene, strontium ranelate, or teriparatide] following a hip fracture), and the all‐cause mortality rates after hip fractures were estimated using a standardized protocol and common data model. The number of hip fractures in 2050 was projected based on trends in the incidence and estimated future population demographics. In total, 4,115,046 hip fractures were identified from 20 databases. The reported age‐ and sex‐standardized incidence rates of hip fractures ranged from 95.1 (95% confidence interval [CI] 94.8–95.4) in Brazil to 315.9 (95% CI 314.0–317.7) in Denmark per 100,000 population. Incidence rates decreased over the study period in most countries; however, the estimated total annual number of hip fractures nearly doubled from 2018 to 2050. Within 1 year following a hip fracture, post‐hip fracture treatment ranged from 11.5% (95% CI 11.1% to 11.9%) in Germany to 50.3% (95% CI 50.0% to 50.7%) in the United Kingdom, and all‐cause mortality rates ranged from 14.4% (95% CI 14.0% to 14.8%) in Singapore to 28.3% (95% CI 28.0% to 28.6%) in the United Kingdom. Males had lower use of anti‐osteoporosis medication than females, higher rates of all‐cause mortality, and a larger increase in the projected number of hip fractures by 2050. Substantial variations exist in the global epidemiology of hip fractures and postfracture outcomes. Our findings inform possible actions to reduce the projected public health burden of osteoporotic fractures among the aging population. © 2023 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong SAR, China.
- Center for Observational Research, Amgen Inc, Thousand Oaks, CA, USA.
- Centre for Surveillance and Applied Research, Public Health Agency of Canada, Ottawa, Canada.
- Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Australia.
- Department of Pharmaceutical and Administrative Sciences, University of Health Sciences and Pharmacy, St Louis, MO, USA.
- Bordeaux PharmacoEpi, INSERM CIC-P1401, Univ. Bordeaux, Bordeaux, France.
ORCID-Profile: Chor-Wing Sing, Cyrus Cooper, Douglas P Kiel, E Michael Lewiecki, Alma B Pedersen, Daniel Prieto-Alhambra, Ju-Young Shin, Ching-Lung Cheung
Förderung
- Medical Research Council
- Amgen
Zitieren
APA
Sing, C. W., Lin, T. C., Bartholomew, S., Bell, J. S., Bennett, C., Beyene, K., Bosco-Levy, P., Bradbury, B. D., Chan, A. H. Y., Chandran, M., Cooper, C., de Ridder, M., Doyon, C. Y., Droz-Perroteau, C., Ganesan, G., Hartikainen, S., Ilomaki, J., Jeong, H. E., Kiel, D. P., …, & Wong, I. C. K. (2023). Global Epidemiology of Hip Fractures: Secular Trends in Incidence Rate, Post‐Fracture Treatment, and All‐Cause Mortality. Journal of Bone and Mineral Research, 38(8), 1064-1075. https://doi.org/10.1002/jbmr.4821
Vancouver
Sing CW, Lin TC, Bartholomew S, Bell JS, Bennett C, Beyene K, et al. Global Epidemiology of Hip Fractures: Secular Trends in Incidence Rate, Post‐Fracture Treatment, and All‐Cause Mortality. Journal of Bone and Mineral Research. 2023;38(8):1064-1075. doi:10.1002/jbmr.4821
BibTeX
@article{Sing2023,
author = {Sing, Chor-Wing and Lin, Tzu-Chieh and Bartholomew, Sharon and Bell, J Simon and Bennett, Corina and Beyene, Kebede and Bosco-Levy, Pauline and Bradbury, Brian D and Chan, Amy Hai Yan and Chandran, Manju and Cooper, Cyrus and de Ridder, Maria and Doyon, Caroline Y and Droz-Perroteau, Cécile and Ganesan, Ganga and Hartikainen, Sirpa and Ilomaki, Jenni and Jeong, Han Eol and Kiel, Douglas P and Kubota, Kiyoshi and Lai, Edward Chia-Cheng and Lange, Jeff L and Lewiecki, E Michael and Lin, Julian and Liu, Jiannong and Maskell, Joe and de Abreu, Mirhelen Mendes and O'Kelly, James and Ooba, Nobuhiro and Pedersen, Alma B and Prats-Uribe, Albert and Prieto-Alhambra, Daniel and Qin, Simon Xiwen and Shin, Ju-Young and Sørensen, Henrik T and Tan, Kelvin Bryan and Thomas, Tracy and Tolppanen, Anna-Maija and Verhamme, Katia M C and Wang, Grace Hsin-Min and Watcharathanakij, Sawaeng and Wood, Stephen J and Cheung, Ching-Lung and Wong, Ian C K},
title = {Global Epidemiology of Hip Fractures: Secular Trends in Incidence Rate, Post‐Fracture Treatment, and All‐Cause Mortality},
journal = {Journal of Bone and Mineral Research},
year = {2023},
volume = {38},
number = {8},
pages = {1064--1075},
doi = {10.1002/jbmr.4821}
}
EUVIMED